FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, cover...
Read More...

FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will re...
Read More...

FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) mark...
Read More...

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.